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GVHD (21% vs 38%, P ≤ .01; and 4% vs 14%, P < .01, respectively). No difference in chronic GVHD, relapse, or nonrelapse mortality 
were found for PBSC or BM. The 2-year overall survival (OS) was 55% versus 56% (P 5 .57) and leukemia-free survival (LFS) was 49% 
versus 54% (P 5 .74) for BM and PBSC, respectively. On multivariate analysis, PBSC were associated with an increased risk of stage II - 
IV (hazard ratio [HR], 2.1; P < .001) and stage III-IV acute GVHD (HR, 3.8; P < .001). For LFS and OS, reduced intensity conditioning 
was the only factor associated with treatment failure (LFS: HR, 1.40; P 5 .04) and relapse (HR, 1.62; P 5 .02). CONCLUSION:  In 
patients with acute leukemia in first or second remission receiving haploidentical transplantation with PT-Cy, the use of PBSC increases  
the  risk of acute  GVHD, whereas  survival  outcomes  are  comparable.  
 
Abstract: Incidence of graft-versus-host disease (GVHD) in haploidentical bone marrow (BM) transplants using posttransplan- 
tion cyclophosphamide (PT-Cy) is low, whereas GVHD using mobilized peripheral blood stem cells (PBSC) ranges between 30% and 
40%. METHODS: To evaluate the effect of stem cell source in haploidentical transplantation with PT-Cy, we analyzed 451 patients 
transplanted for acute myeloid leukemia or acute lymphoblastic leukemia reported to the European Society for Blood and Marrow  
Transplantation. RESULTS: BM was used in 260 patients, and PBSC were used in 191 patients. The median follow-up was 21 months. 
Engraftment was lower in BM (92% vs 95%, P < 0.001). BM was associated with a lower incidence of stage II-IV and stage III-IV acute 
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INTRODUCTION 
The role of stem cell source in the setting of related or unrelated donor transplant (hematopoietic stem cell transplantation 
[HSCT]) and a myeloablative conditioning (MAC) regimen has been evaluated in randomized trials, showing an excess of 
chronic graft-versus-host disease (GVHD) with peripheral blood stem cells (PBSC) as the stem cell source, with no differ- 
ences in disease-free and overall survival.
1
 Subsequently, Eapen et al
2
 did not confirm an increased risk of chronic GVHD 
with PBSC grafts in a registry-based study analyzing HSCT with a reduced intensity conditioning (RIC) regimen from 
unrelated donors. 
The number of unmanipulated haploidentical stem cell transplantations (haplo-SCT) in adult patients with hemato- 
logical malignancies such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) is increasing con- 
stantly.
3
 Haplo-SCT is performed with a different conditioning regimen and GVHD prophylaxis,
4
 with comparable 
results to HSCT from unrelated donors.
5,6
 
Historically, Luznik et al
7
 pioneered the use of posttransplantion cyclophosphamide (PT-Cy) in the setting of RIC 
using bone marrow (BM) as stem cell source. This protocol is associated with a low incidence of acute and chronic 
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GVHD and low transplantation-related mortality for 
older patients, although disease recurrence is rather high, 
partially because of the high risk of disease in most 
patients.
8
 
To overcome the high incidence of relapse with RIC 
haplo-SCT, some authors effectively reported the applica- 
tion of BM and PT-Cy with myeloablative regimes 
(MAC)
9
 and also with the use of PBSC
10
 as a stem cell 
source. The incidence of GVHD in haploidentical trans- 
plantations using PBSC grafts ranges from 30% to 40% 
in single-center reports.
11
 
Recently, O’Donnell et al
12
 reported comparable 
results in recipients of BM versus PBSC grafts in the 
nonablative setting in a matched paired analysis on 
patients who received transplants for several hematologi- 
cal malignancies. 
The effect of stem cell source in recipients of haploi- 
dentical transplants has been reported by Bashey et al
13
 in 
a series of 681 patients with hematologic malignancy 
receiving PT-Cy as GVHD prophylaxis. 
The goal of this study was to investigate the effects 
of stem cell source in non–T-cell–depleted haploidentical 
transplantation using PT-Cy. We analyzed patients who 
received transplants for AML or ALL who were in first or 
second complete remission (CR) and reported to the 
European Society for Blood and Marrow Transplantation 
(EBMT) registry from 2010 to 2014. 
 
 
METHODS 
Study Design 
This is a retrospective registry-based analysis on behalf of 
the Acute Leukaemia Working Party (ALWP) of the 
EBMT. 
The EBMT is a voluntary working group of more 
than 500 transplantation centers that are required to 
report all consecutive stem cell transplantations and 
follow-up once a year. Audits are routinely performed to 
determine the accuracy of the data. 
All adults (age >18 years) with ALL or AML in 
first or second CR (CR1 or CR2) at transplantation, 
reported to Promise-EBMT, who underwent haplo-SCT 
using PT-Cy as first allogeneic HSCT between 2010 and 
2014 were analyzed. Haplo was defined as recipient- 
donor number of human leukocyte antigen (HLA) mis- 
matches >2. 
A total of 451 patients were reported from 99 trans- 
plantation centers, including 260 patients receiving BM 
and 191 patients receiving PBSC as a stem cell source. 
This study was approved by the ALWP of the 
EBMT institutional review board. It was conducted in 
accordance with the Declaration of Helsinki and Good 
Clinical Practice guidelines. All patients or legal guardians 
provided written informed consent authorizing the use of 
clinical information for research purposes. 
 
Endpoints and Definitions 
The primary endpoint was leukemia-free survival (LFS). 
Secondary endpoints were neutrophil engraftment, acute 
GVHD (aGVHD) and chronic GVHD (cGVHD), 
relapse incidence, nonrelapse mortality (NRM), GVHD- 
free and relapse-free survival (GRFS), and overall survival 
(OS). Refined GRFS
14
 was defined as survival without 
the following events: stage III-IV aGVHD, severe 
cGVHD, disease relapse, or death from any cause after 
haplo-SCT. LFS was calculated until the date of first 
relapse, death from any cause or the last follow-up for 
patients in CR. Relapse was defined as disease recurrence 
and appearance of blasts in the peripheral blood or BM 
(>5%) after CR. NRM was defined as death from any 
cause other than relapse. Acute GVHD was staged accord- 
ing to the modified Seattle Glucksberg criteria
15
 and 
cGVHD according to the revised Seattle criteria.
16
 Neu- 
trophil engraftment was defined as first of 3 consecutive 
days with a neutrophil count of at least 0.5 3 10
9
/L. 
MAC was defined as a regimen containing either 
total body irradiation with a dose greater than 6 Gray, a 
total dose of oral busulfan greater than 8 mg/kg, or a total 
dose of intravenous busulfan >6.4 mg/kg or melphalan at 
doses >140 mg/m2. In addition, regimens containing 2 
alkylating agents were considered as MAC. All other regi- 
mens were defined as RIC. 
 
Statistical Analysis 
GRFS, LFS, and OS were estimated using the Kaplan- 
Meier method. Cumulative incidence functions were used 
to estimate neutrophil engraftment, aGVHD, cGVHD, 
relapse incidence, and NRM. Competing risks were death 
for relapse incidence, relapse for NRM, relapse or death 
for aGVHD and cGVHD. Univariate analyses were done 
using the log-rank test for GRFS, OS and LFS, and Gray’s 
test for cumulative incidence. 
For univariate analysis, comparisons were made by 
using chi-squared tests for categorical and Mann-Whitney 
tests for continuous variables. Multivariate analyses were 
performed using the Cox proportional hazard model. 
Stem cell source, diagnosis, disease status, age at 
transplantation, transplantation year, cytomegalovirus 
serostatus (donor and recipient negative vs other 
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TABLE 1. Patient and Transplantation Characteristics 
Characteristic BM (n 5 260) PBSC (n 5 191) P
a
 
 
Follow-up, mo, median (range) 22.8 (2.4-62.4) 18.3 (1.6-50.5) .42 
Patient age, y, median (range) 46.5 (18.4-74.8) 44.4 (18.2-74.9) .88 
Time from diagnosis to transplantation, mo, median (range) 7.7 (2-100.3) 8.1 (2-237.9) .56 
Year of transplantation, median (range) 2013 (2010-2014) 2013 (2010-2014) .15 
AML, n (%) 195 (75) 136 (71) .36 
ALL, n (%) 65 (25) 55 (29)  
CR1, n (%) 174 (67) 131 (69) .70 
CR2, n (%) 86 (33) 60 (31)  
De novo AL, n (%) 225 (87) 155 (81) .12 
Secondary AL, n (%) 35 (13) 36 (19)  
CMV D2/R2, n (%) 25 (10) 18 (9) .04 
CMV D1/R1, n (%) 153 (60) 132 (70)  
MAC, n (%) 159 (61) 93 (49) .008 
RIC, n (%) 101 (39) 98 (51)  
No ATG, n (%) 247 (95) 178 (93) .41 
ATG, n (%) 13 (5) 13 (7)  
Abbreviations: AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; CMV, 
cytomegalovirus; CR, complete response; MAC, myeloablative conditioning; PBSC, peripheral blood stem cells; RIC, reduced intensity conditioning. 
a Significant P values are presented in boldface type. 
 
combination), conditioning regimen and center experi- 
ence were included in the final model. To test for center 
effect, we introduced a random effect or frailty for each 
center into the model. 
The significance level was fixed at .05, and P values 
were 2-sided. Statistical analyses were performed using 
SPSS version 22 (IBM, Armonk, NY) and R version 3.2.3 
(R Development Core Team, Vienna, Austria) software 
packages. 
 
RESULTS 
Patient and Transplantation Characteristics 
Table 1 summarizes the main patient and transplantation 
characteristics. A total of 451 patients were reported, 260 
of whom received BM and 191 of whom received PBSC 
as a stem cell source. The majority of the patients in both 
groups underwent transplantation for AML (73%) in 
CR1 (67%). The median age at transplantation was 45 
years (range, 18-76 years). 
Median follow-up was longer for patients receiving 
BM (22.8 vs 18.3 months) and those patients were more 
likely transplanted with MAC (61% vs 49% [P 5 .008]). 
The combination of thiotepa, busulfan, and fludarabine 
or FluCy and low-dose total body irradiation were the 
most common conditioning regimen used in MAC and 
RIC setting, respectively. 
All patients received PT-Cy as GVHD prophylaxis, 
mainly in combination with calcineurin inhibitor and myco- 
phenolate mofetil, according to the transplantation center’s 
policy. The use of antithymocyte globulin (ATG) use was 
not different for the 2 groups (5% vs 7% [P 5 .41]). 
The median CD341 was 2.8 3 10
6
/kg and 6.8 3 
10
6
/kg for BM and PBSC, respectively (P < .001). 
Neutrophil Engraftment and GVHD 
The cumulative incidence of neutrophil engraftment was 
92% and 95% for patients receiving BM and PBSC, 
respectively (P < .001). The time to neutrophil engraft- 
ment was longer in the BM group (18 vs 17 days [P < 
.001]). 
The cumulative incidence of day 100 stage II-IV 
aGVHD and 1-year cGVHD were 28% and 35%, 
respectively. 
On univariate analysis (Table 2), patients who 
underwent transplantation with BM had a lower inci- 
dence of stage II-IV and stage III-IV aGVHD (21% vs 
38% [P ≤ .01] and 4% vs 14% [P ≤ 0.01], respectively) 
(Fig. 1a). On adjusted multivariate analysis (Table 3), 
PBSC were independently associated with increased risk 
of stage II-IV aGVHD (hazard ratio [HR], 2.1; 95% con- 
fidence interval [CI], 1.46-3.0; P < .001) and stage III-IV 
aGVHD (HR, 3.8; 95% CI, 1.7-8.2; P < .001). 
No difference in cGVHD (36% vs 32% [P 5 .28]) 
was observed in recipients of BM versus PBSC grafts 
(Fig. 1b). Similarly, type of stem cell (PBSC vs BM) was 
not associated with cGVHD (HR, 1.0; 95% CI, 0.58-1.9; 
P 5 .88) on multivariate analysis (Table 3). 
 
Relapse and NRM 
At 2 years, the cumulative incidence of relapse was 25% 
with no difference according to the stem cell source (BM 
26% vs PBSC 22% [P 5 .38]) (Fig. 1c). The cumulative 
incidence of relapse was 22.4% for AML and 30.8% for 
  
 
 
 
 
TABLE 2. Univariate Analysis 
 
  
Relapse 
 
NRM 
 
LFS 
 
OS 
 
GRFS 
aGVHD 
Stage II-IV 
aGVHD 
Stage III-IV 
 
cGVHD 
 
ext. cGVHD 
BM 
      
4 (2-6.9) 
  
 26.8 (21.2-32.6) 23.5 (18.1-29.3) 49.4 (42.7-56.1) 55.5 (48.7-62.3) 44 (37.5-50.5) 21.6 (16.7-26.9)  36.4 (30-42.8) 12.3 (8.3-17.1) 
PBSC       13.8 (9.3-19.3)   
 21.9 (15.9-28.6) 23.5 (17.5-30) 54.4 (46.8-62.1) 55.6 (47.8-63.5) 43.2 (35.7-50.7) 38.3 (31.2-45.3)  32.1 (24.8-39.6) 10.3 (6.1-15.7) 
P .38 .60 .74 .57 .39 .0004 .0001 .28 .48 
Age <45 y       10.7 (7-15.2)   
 28.2 (22-34.6) 22 (16.5-28) 49.4 (42.3-56.5) 56.9 (49.6-64.1) 39.2 (32.3-46) 29.8 (23.8-36)  33.7 (26.9-40.6) 11.4 (7.3-16.6) 
Age ≤45 y 
21.1 (15.8-27) 25.3 (19.3-31.7) 53.5 (46.3-60.7) 54 (46.6-61.4) 48 (41-55) 27.3 (21.5-33.4) 
5.5 (3-9.1) 
35.6 (28.8-42.5) 11.4 (7.4-16.4) 
P .13 .40 .54 .54 .10 .48 .04 .68 .99 
Interval from diagnosis       8.8 (5.5-13.1)   
to haplo-Tx <8 mo 
Interval from diagnosis 
22.7 (17.1-28.7) 21 (15.5-27.1) 55.9 (48.8-63.1) 59.5 (52.2-66.8) 47.7 (40.7-54.6) 26.5 (20.8-32.6)  
7.3 (4.4-11.3) 
39.7 (32.6-46.7) 12.6 (8.3-17.8) 
to haplo-Tx ≤8 mo 26.6 (20.6-32.9) 26.3 (20.3-32.6) 47 (39.9-54.1) 51.5 (44.2-58.8) 39.7 (32.9-46.6) 30.6 (24.5-36.8)  29.5 (23.1-36.3) 10.2 (6.4-15.1) 
P .44 .27 .10 .07 .17 .50 .56 .02 .45 
Year <2013  
31.7 (24.1-39.6) 
 
19.7 (13.5-26.8) 
 
48.1 (39.7-56.5) 
 
53.7 (45.3-62.1) 
 
38.8 (30.6-47) 
 
23.8 (17.1-31.2) 
7.2 (3.7-12.3)  
38.6 (30.3-46.7) 
 
14.8 (9.4-21.4) 
Year ≤2013 
20.7 (16-25.8) 25.8 (20.5-31.4) 53.4 (47.1-59.7) 56.8 (50.3-63.3) 46.4 (40.3-52.5) 30.8 (25.6-36.2) 
8.5 (5.7-12.1) 
32.7 (26.7-38.8) 9.6 (6.2-13.8) 
P .02 .16 .43 .60 .28 .15 .65 .15 .11 
AML       7.6 (5-10.9)   
 22.4 (17.8-27.4) 24.4 (19.6-29.5) 53 (47.2-58.9) 56 (50-62) 44.7 (38.9-50.4) 26 (21.3-31)  33 (27.5-38.6) 11.6 (8.2-15.8) 
ALL       9.5 (5-15.7)   
 30.8 (22.2-39.9) 21.5 (14.1-29.9) 47.1 (37.2-57) 53.8 (43.7-64) 40.6 (31.2-50) 35.5 (26.9-44.3)  39.3 (29.5-49) 10.9 (5.7-17.9) 
P .04 .38 .31 .79 .23 .04 .50 .22 .96 
CR1       8.9 (6-12.5)   
 22.2 (17.4-27.4) 24.4 (19.3-29.8) 53.1 (46.9-59.4) 57.7 (51.4-64) 46.5 (40.6-52.5) 24.7 (19.9-29.7)  33.8 (27.9-39.7) 10.2 (6.9-14.4) 
CR2       6.4 (3.2-11.3)   
 29.6 (22-37.5) 22.2 (15.5-29.7) 48 (39.3-56.6) 51.1 (42.1-60.1) 37.9 (29.5-46.3) 36.7 (28.7-44.7)  36.2 (27.8-44.6) 13.6 (8.3-20.3) 
P .08 .50 .36 .33 .32 .02 .38 .75 .38 
De novo AL       8.8 (6.2-12)   
 25 (20.4-29.7) 23.6 (19.1-28.4) 51.2 (45.7-56.7) 55.7 (50-61.4) 43 (37.7-48.4) 29.5 (24.9-34.3)  36.2 (30.9-41.6) 12.4 (9-16.4) 
Secondary AL       4.4 (1.2-11.3)   
 23 (13.5-33.9) 23.9 (14.4-34.7) 52.8 (40.5-65) 53.9 (41.3-66.6) 47.1 (34.9-59.3) 23.5 (14.2-34.2)  26.6 (15.9-38.5) 6.3 (2-14.3) 
P .79 .38 .64 .20 .69 .35 .22 .11 .18 
No F->M  
24.1 (19.4-29.1) 
 
23.4 (18.8-28.4) 
 
52.2 (46.5-58) 
 
56 (50.1-61.9) 
 
45.7 (40.1-51.4) 
 
28.6 (23.8-33.6) 
8.5 (5.8-11.8)  
31.9 (26.5-37.4) 
 
9.5 (6.4-13.2) 
F->M       6.8 (3-12.8)   
 26.2 (17.9-35.4) 24.4 (16-33.7) 49.1 (38.7-59.5) 53.6 (42.9-64.4) 37.4 (27.8-47.1) 28.3 (19.9-37.3)  42.9 (32.3-53) 17.4 (10.4-25.9) 
P .84 .76 .78 .96 .26 .97 .60 .10 .04 
CMV D2/R2       7.7 (1.9-18.8)   
 28 (14.9-42.6) 34.3 (18.8-50.5) 37.7 (21.3-54.1) 38 (20.5-55.5) 30 (15.4-44.6) 31 (17.2-45.9)  26.4 (13.4-41.3) 13.5 (4.8-26.7) 
CMV D1/R2       6.5 (1.1-18.9)   
 20.6 (7.9-37.4) 19.6 (7.7-35.5) 59.8 (41.7-77.8) 65.9 (48.5-83.3) 52.7 (35-70.3) 29 (14.3-45.6)  39.6 (21.3-57.5) 14.3 (4.3-29.9) 
CMV D2/R1       3.8 (1-9.9)   
 32.7 (22.1-43.6) 14.2 (7.1-23.5) 52.7 (40.9-64.5) 55.1 (43-67.2) 48 (36.4-59.7) 14.3 (7.5-23.1)  38.1 (25.9-50.3) 7.2 (2.6-15) 
CMV D1/R1       9.8 (6.7-13.7)   
4
 
  
 
ALL (P 5 .04) and 22.2% and 29.6% for patients who 
underwent transplantation in CR1 and CR2 (P 5 .08), 
respectively (Table 2). 
aGVHD and cGVHD were not associated with 
relapse incidence in a time-dependent fashion model 
(data not shown). The overall 2-year NRM was 23%, 
with no difference for BM or PBSC recipients (23% vs 
23% [P 5 .61]) (Table 2) (Fig. 1d). The main causes of 
death were disease recurrence (BM, 33%; PBSC, 39%), 
infection (BM, 39%; PBSC, 33%), and GVHD (BM, 
14%; PBSC, 17%). 
On multivariate analysis (Table 3), the type of stem 
cell graft (PBSC vs BM) was not associated with relapse 
(HR, 0.8; 95% CI, 0.51-1.15; P 5 .21) or NRM (HR, 
0.81; 95% CI, 0.49-1.32; P 5 .4). RIC regimen was the 
only factor associated with an increased risk of relapse 
(HR, 1.62; 95% CI, 1.07-2.44; P 5 .02). 
 
OS, LFS, and GRFS 
OS, LFS, and GRFS at 2 years were 55%, 51%, and 44%, 
respectively. According to stem cell source, OS was 55% 
versus 56% (P 5 .57), LFS was 49% versus 54% (P  5 
.74), and GRFS was 44% and 43% (P 5 .39) for BM and 
PBSC, respectively (Fig. 2). LFS was 53% for patients 
who underwent transplantation for AML and 47% for 
those with ALL (P 5 .32), and it was 56% and 46% (P 5 
 
TABLE 3. Multivariate Analysis 
 
HR 95% CI P
a
 
aGVHD stage II-IV 
   
PBSC vs BM 2.09 1.45-3.01 .0007 
Age per 10 years 1.03 0.91-1.18 .57 
Year of Tx 1.23 1.02-1.47 .02 
ALL vs AML 1.58 1.06-2.35 .02 
CR2 vs CR1 1.71 1.17-2.49 .005 
CMV D2/R2 vs other 1.00 0.54-1.84 .98 
RIC vs MAC 0.79 0.54-1.16 .23 
Center (frailty)   .92 
cGVHD    
PBSC vs BM 1.04 0.57-1.90 .87 
Age per 10 years 0.98 0.84-1.14 .84 
Year of Tx 0.90 0.75-1.08 .26 
ALL vs AML 1.21 0.79-1.87 .36 
CR2 vs CR1 1.01 0.67-1.50 .95 
CMV D2/R2 vs other 0.83 0.40-1.71 .62 
RIC vs MAC 1.40 0.88-2.24 .14 
Center (frailty)   .0003 
Relapse    
PBSC vs BM 0.76 0.51-1.15 .21 
Age per 10 years 0.93 0.81-1.08 .38 
Year of Tx 0.91 0.76-1.09 .32 
ALL vs AML 1.50 0.97-2.31 .06 
CR2 vs CR1 1.29 0.85-1.94 .22 
CMV D2/R2 vs other 1.14 0.60-2.17 .68 
RIC vs MAC 1.61 1.06-2.44 .02 
Center (frailty)   .31 
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TABLE 3. Continued 
 
 
 
NRM 
 
 
HR 95% CI P
a
 
DISCUSSION 
The number of transplantations from an HLA partially 
matched related donor
17
 has increased in recent years due 
to the use of novel strategies without ex vivo T cell deple- 
 
 
 
 
 
 
 
 
 
 
 
.27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations: aGVHD, acute graft-versus-host disease; ALL, acute lym- 
phoblastic leukemia; AML, acute myeloid leukemia; BM, bone marrow; 
cGVHD, chronic graft-versus-host disease; CMV, cytomegalovirus; CR, 
complete response; GRFS, GVHD-free and relapse-free survival; LFS, 
leukemia-free survival; MAC, myeloablative conditioning; NRM, nonrelapse 
mortality; OS, overall survival; PBSC, peripheral blood stem cells; RIC, 
reduced intensity conditioning; Tx, transplantation. 
a Significant P values are presented in boldface type. 
 
 
 
 
 
.004) for MAC versus RIC recipients, respectively (Table 
2). On multivariate analysis (Table 3), the use of BM or 
PBSC was not associated with GRFS (HR, 0.96; 95% CI 
0.69-1.33; P 5 .82), LFS (HR, 0.74; 95% CI, 0.52-1.04; 
P 5 .08) and OS (HR, 0.79; 95% CI, 0.54-1.15; P 5 
.23). For LFS and OS, the use of RIC regimen was the 
only factor associated with higher risk of treatment failure 
(LFS: HR, 1.40; 95% CI, 1.01-1.93; P 5 .04; OS:  HR, 
1.5; 95% CI, 1.07-2.14; P 5 .02). Center effect, which 
was entered as a frailty variable in a multivariate model, 
was significant for NRM, LFS, GRFS, OS, and cGVHD 
(Table 3). 
donor by using data reported to the ALWP-EBMT 
registry. 
In our study, OS and LFS were not different using 
BM versus PBSC grafts, consistent with data of prospec- 
tive and retrospective studies using MAC or RIC in sib- 
ling and unrelated donors.
22,23
 Engraftment of myeloid 
cells was higher with PBSC grafts compared with BM 
grafts. This finding is in agreement with many previous 
reports indicating faster engraftment with PBSC versus 
BM grafts in different transplantation settings.
1
 
In the haploidentical setting, retrospective studies 
comparing the type of stem cell source using PT-Cy were 
published, showing no difference in the incidence of 
GVHD and survival.
12,24,25
 These analyses included RIC 
transplants and patients with heterogeneous myeloid and 
lymphoid malignancies. 
Interestingly, an advantage in survival and 
progression-free survival of PBSC over BM has been 
recently reported in 62 patients receiving a haploidentical 
transplant for advanced Hodgkin disease.
26
 The biology 
of this disease and its sensitivity to the immunological 
 
  
PBSC vs BM 0.80 0.49-1.32 .40 tion. Non–T-cell–depleted approaches are attractive 
Age per 10 years 1.14 0.98-1.34 
.08 
because they require no expertise in graft manipulation or 
Year of Tx 1.04 0.85-1.28 .66 
ALL vs AML 1.02 0.61-1.70 .93 CD341 cell selection and are affordable for most trans- 
CR2 vs CR1 0.81 0.51-1.29 
.39 plantation centers. In addition, familiar donors are easily 
CMV D2/R2 vs other 1.57 0.82-2.99 .17 
RIC vs MAC 1.25 0.79-1.99 .33 available and the procedure may be organized quickly, 
Center (frailty)   .04 minimizing delay. The attractiveness of haplo-SCT 
LFS 
PBSC vs BM 
 
0.73 
 
0.51-1.04 
 
.08 should be verified by a detailed analysis of the results, 
Age per 10 years 1.03 0.93-1.15 .53 because the potential advantages may be counterbalanced 
Year of Tx 
ALL vs AML 
0.95 
1.28 
0.83-1.09 
0.92-1.80 
.54 
.14 by increased risk of immune-related complications. 
CR2 vs CR1 1.03 0.75-1.40 .84 Despite short follow-up, several studies have reported 
CMV D2/R2 vs other 1.29 0.81-2.05  
RIC vs MAC 1.39 1.01-1.93 .04 comparable outcomes after haplo-SCT and HLA- 
Center (frailty) .06 matched sibling and unrelated donors.
18-20
 
OS    The application of unmanipulated haploidentical 
PBSC vs BM 0.79 0.54-1.15 .23 
Age per 10 years 1.11 0.99-1.24 .06 transplantation to adults with different hematological 
Year of Tx 0.95 0.82-1.10 
.54 diseases has led to investigations of the feasibility of using 
ALL vs AML 1.24 0.86-1.79 .24 
CR2 vs CR1 1.07 0.77-1.49 .65 different stem cell sources in this setting. The first reports 
CMV D2/R2 vs other 1.21 0.74-1.98 .43 using BM, mainly in a non-myeloablative setting with 
RIC vs MAC 1.51 1.06-2.13 .01 
Center (frailty)   .01 low-dose total body irradiation, were associated with low 
GRFS    incidence of both aGVHD and cGVHD, counterbal- 
PBSC vs BM 0.96 0.69-1.33 .82 anced by an excess in disease recurrence.
21
 This 
Age per 10 years 1.01 0.92-1.12 .72  
Year of Tx 0.95 0.84-1.08 .44 prompted some investigators to assess the use of PBSC in 
ALL vs AML 1.23 0.90-1.67 .18 this setting, facing the risk of severe GVHD.
11
 With the 
CR2 vs CR1 1.03 0.78-1.37 .81  
CMV D2/R2 vs other 1.36 0.89-2.09 .15 aim of analyzing the effect of stem cell sources in patients 
RIC vs MAC 1.05 0.78-1.42 .72 with acute leukemia, we compared the transplantation 
Center (frailty)   .05 outcomes with BM versus PBSC from a haploidentical 
 
  
 
Figure 1. (A) Acute graft-versus-host disease stage III-IV. (B) Chronic graft-versus-host disease. (C) Relapse incidence. (D) Nonre- 
lapse mortality for bone marrow and peripheral blood stem cell recipients. 
 
 
 
 
effect mediated by the haploidentical cells, may in part 
explain this finding. 
Bashey et al
13
 reported comparable OS and mortal- 
ity between BM and PBSC recipients in a large series of 
patients with lymphoid and myeloid malignancies. In this 
report, despite the increased risk of aGVHD using PBSC, 
there was a reduced risk of relapse compared with BM. 
Importantly in this series, the BM group received a high 
proportion of RIC regimen using low-dose total body 
irradiation, which could partly explain the difference in 
our results, in which the graft source did not influence the 
relapse risk. In our population, given the different 
 
techniques developed in Europe in the haploidentical 
transplantation setting, there was a higher proportion of 
MAC in the BM group, and there was no interaction 
between the source of stem cells and conditioning inten- 
sity for all endpoints evaluated. 
Consistent with the CIBMTR study, we observed 
significant differences in incidence of severe aGVHD 
comparing PBSC and BM grafts in a homogenous group 
of patients with leukemia. In accordance, BM with PT- 
Cy was reported to be associated with a low incidence of 
GVHD in different single-center reports.
7,27
 The action 
of PT-Cy in preventing GVHD after BM graft has been 
 
  
  
 
 
Figure 2. (A) Overall survival. (B) Leukemia-free survival for bone marrow and peripheral blood stem cell recipients. 
 
 
elucidated, mediating selective in vivo destruction of 
alloreactive T cells, induction of tolerance, and intrathy- 
mic clonal deletion of alloreactive T lymphocytes.
28
 
One could argue that the lymphocyte count infused 
with the unmanipulated PBSC graft in the setting of a full 
haplotype mismatch could be responsible for an increase 
of aGVHD; however, one of the limitations of our 
registry-based study is the lack of CD31 cell number 
infused with the graft. 
We did not find a difference in cGVHD according 
to stem cell source. This finding is consistent with reports 
in unrelated
2
 and haploidentical
12
 settings using RIC 
regimens. 
Of note, in our study the difference in aGVHD was 
not reflected by an excess of NRM, nor were GRFS, LFS, 
and OS. This may also be due to the substantial improve- 
ments in supportive care after allogeneic transplantation 
over the years, allowing better survival and reduction of 
treatment-related toxicities. There is a learning curve associ- 
ated with the procedure, and transplantation centers are 
using it more frequently for the management of haploident- 
ical transplantation complications. 
Therefore, we have adjusted the comparison of BM 
versus PBSC using a random effect for each center that 
could reflect the variability between centers due to all fac- 
tors, some of which may not be reported in such a retro- 
spective study. We confirm that the center experience is 
not a confounding factor for the comparison between the 
2 sources of stem cells in our study as the 2 types of centers 
are rather well balanced between the use of BM and 
PBSC. 
The type of conditioning regimen was an indepen- 
dent factor associated with relapse and LFS and OS, with 
RIC associated with treatment failure. RIC regimens are 
 
  
  
 
associated with a greater risk of disease relapse. Large reg- 
istry studies have shown that the use of an RIC regimen 
was associated with a higher risk of relapse but also a lower 
incidence of NRM, translating to similar OS and 
LFS.29,30 
Other investigators have not detected differences in 
outcomes with RIC versus MAC in unmanipulated haploi- 
dentical transplantation; however, this series included a quite 
heterogeneous population of patients with different disease 
status and several platforms of GVHD prophylaxis.
31
 
We are aware that there may be unmeasured factors 
that have not been considered in our study, which is a lim- 
itation when conducting any retrospective study. 
With the available data, our study indicates that in 
patients with acute leukemia in CR1 or CR2 who under- 
went haploidentical transplantation with PT-Cy, the use 
of PBSC significantly increased the risk of aGVHD, 
whereas survival outcomes were comparable. Importantly, 
with a follow-up of 2 years, cGVHD, which is a major 
contributor to long-term morbidity and mortality, is simi- 
lar using PBSC or BM grafts. 
The ultimate choice of graft source depends on the 
design of the full transplantation package based on trans- 
plantation center experience. Our results suggest that a 
prospective comparative trial of PBSC versus BM in PT- 
Cy haploidentical transplantation could help establish a 
standard in the field. 
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